Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
| Status: | Terminated |
|---|---|
| Conditions: | Allergy, Lymphoma |
| Therapuetic Areas: | Oncology, Otolaryngology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/21/2016 |
| Start Date: | February 2012 |
The purpose of this randomized, double-blinded, placebo-controlled study is to test the
hypothesis that administration of aprepitant will decrease the severity of pruritus in
patients with Sèzary Syndrome.
hypothesis that administration of aprepitant will decrease the severity of pruritus in
patients with Sèzary Syndrome.
Inclusion Criteria:
- Known Sezary Syndrome
- Pruritus uncontrolled by conventional treatment. Baseline visual analogue scale > 4.
- Age 18 through 80 years of age.
- Stable medication regimens for both Sezary Syndrome and pruritus for 3 months prior
to study participation.
Exclusion Criteria:
- Known hepatic impairment (defined as liver function tests >3 times the upper limit of
normal).
- Pregnancy (all women of child-bearing potential will undergo urine beta-hcg testing).
- Concurrent use of pimozide, terfenadine, astemizole, or cisapride.
We found this trial at
1
site
1211 Medical Center Dr
Nashville, Tennessee 37232
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
Click here to add this to my saved trials
